Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jurij Zdovc"'
Publikováno v:
Bone & Joint Open, Vol 1, Iss 12, Pp 737-742 (2020)
Aims: Synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells (%PMN) are elevated at periprosthetic joint infection (PJI). Leucocytes produce different interleukins (IL), including IL-6, so we hypothesized that synovial
Externí odkaz:
https://doaj.org/article/0123addfbe36408bad3c783c35733971
Publikováno v:
Acta Orthopaedica, Vol 91, Iss 6, Pp 675-681 (2020)
Background and purpose — The accuracy of conventional navigation systems depends on precise registration of bony landmarks. We investigated the clinical use of electromagnetic navigation (EMN), with a unique device for precise determination of the
Externí odkaz:
https://doaj.org/article/c1e546ce8ae54e6da1fcfcaf70517555
Publikováno v:
Molecules, Vol 26, Iss 6, p 1787 (2021)
Monoclonal antibodies (mAbs) have been extensively developed over the past few years, for the treatment of various inflammatory diseases. They are large molecules characterized by complex pharmacokinetic and pharmacodynamic properties. Therapeutic dr
Externí odkaz:
https://doaj.org/article/cd2a1b9160024314b4bf9914067d50d3
Publikováno v:
Bone & Joint Open
Bone & Joint Open, Vol 1, Iss 12, Pp 737-742 (2020)
Bone & Joint Open, Vol 1, Iss 12, Pp 737-742 (2020)
Aims Synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells (%PMN) are elevated at periprosthetic joint infection (PJI). Leucocytes produce different interleukins (IL), including IL-6, so we hypothesized that synovial f
Publikováno v:
Molecules, vol. 26, no. 6, 1787, 2021.
Molecules
Molecules, Vol 26, Iss 1787, p 1787 (2021)
Molecules
Molecules, Vol 26, Iss 1787, p 1787 (2021)
Monoclonal antibodies (mAbs) have been extensively developed over the past few years, for the treatment of various inflammatory diseases. They are large molecules characterized by complex pharmacokinetic and pharmacodynamic properties. Therapeutic dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b303f40b82273849fefcef03c3edf68a
https://repozitorij.uni-lj.si/Dokument.php?id=154081&dn=
https://repozitorij.uni-lj.si/Dokument.php?id=154081&dn=
Autor:
Jurij Hanžel, Debby Thomas, Barbara Ostanek, Erwin Dreesen, Jurij Zdovc, Gregor Novak, Matic Koželj, Tomaž Vovk, Nejc Sever, Tina Kurent, Iztok Grabnar, David Drobne, Nataša Smrekar, Borut Štabuc
Publikováno v:
Pharmaceutics
Volume 13
Issue 10
Pharmaceutics, vol. 13, no. 10, 1587, 2021.
Pharmaceutics, Vol 13, Iss 1587, p 1587 (2021)
Volume 13
Issue 10
Pharmaceutics, vol. 13, no. 10, 1587, 2021.
Pharmaceutics, Vol 13, Iss 1587, p 1587 (2021)
Ustekinumab is a monoclonal antibody used in Crohn’s disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic–pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice. We aimed to develop a
Autor:
Gregor Novak, Tina Kurent, Ana Špes Hlastec, Iztok Grabnar, Nejc Sever, Borut Štabuc, Jurij Zdovc, Jurij Hanžel, Matic Koželj, David Drobne, Nataša Smrekar
Publikováno v:
European journal of gastroenterologyhepatology. 33(1S Suppl 1)
OBJECTIVES Some patients with Crohn's disease do not achieve remission with the approved maintenance dosing of ustekinumab every 8 weeks, possibly due to insufficient drug exposure. We aimed to study the exposure-response relationship for endoscopic
Autor:
Katarina Javornik, Erwin Dreesen, Katja Tuta, Jurij Zdovc, Tomaž Vovk, Matic Koželj, Gregor Novak, Debby Thomas, Tina Kurent, Iztok Grabnar, Nejc Sever, David Drobne, Nataša Smrekar, Borut Štabuc, Jurij Hanžel
BACKGROUND & AIMS: Little is known about the relationship between ustekinumab exposure during the first 2 weeks of treatment and outcomes of patients with Crohn's disease (CD). We investigated the relationship between serum concentrations of ustekinu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77ef83b0a302944f521eba960dec5ed
https://lirias.kuleuven.be/handle/123456789/652078
https://lirias.kuleuven.be/handle/123456789/652078
Publikováno v:
Acta Pharmaceutica
Volume 70
Issue 3
Acta Pharmaceutica, Vol 70, Iss 3, Pp 359-371 (2020)
Volume 70
Issue 3
Acta Pharmaceutica, Vol 70, Iss 3, Pp 359-371 (2020)
Films for buccal application are a slowly emerging new platform for drug delivery. There remains a lack of analytical techniques for the determination of in vitro active pharmaceutical ingredient release. The aim here was to develop an alternative me
Publikováno v:
Journal of clinical pharmacy and therapeuticsREFERENCES. 44(5)
What is known and objectives Gentamicin is often used for the treatment of Gram-negative infections. Due to pharmacokinetic variability in paediatric patients, appropriate dosing of gentamicin in the paediatric population is challenging. This article